800.850.4306
  • Facebook
  • Twitter
  • LinkedIn
  • Facebook
  • Twitter
  • LinkedIn
  • News
  • Media
  • About Us
  • Contact
Biologics by McKesson
  • Patients
  • Providers
  • Biopharma
    • Biologics Rare and Orphan Care
  • Payers
Select Page

XPOVIO (selinexor), FDA Approved for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL), Available at Biologics by McKesson

Jun 29, 2020 | Press Release

CARY, N.C., June 29, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology, rare diseases and other complex therapeutic areas, was selected by Karyopharm Therapeutics, Inc. as a specialty pharmacy provider for XPOVIO® (selinexor) for...

Brandon Tom Appointed New General Manager of Biologics by McKesson

Jun 22, 2020 | Press Release

CARY, N.C., June 22, 2020—Biologics by McKesson, an independent specialty pharmacy and patient services company specializing in oncology, rare diseases and other complex therapeutic areas, is pleased to announce that Brandon Tom, PharmD, was named its new general...

QINLOCK (Ripretinib), FDA Approved for Treatment of Gastrointestinal Stromal Tumors (GIST), Available at Biologics by McKesson

Jun 2, 2020 | Press Release

CARY, N.C., June 2, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Deciphera Pharmaceuticals as a specialty pharmacy provider for QINLOCK™ (ripretinib) for the treatment of adult patients...

RETEVMO (selpercatinib), FDA-Approved for Treatment of RET-driven Lung and Thyroid Cancers, Available at Biologics by McKesson

Jun 1, 2020 | Press Release

CARY, N.C., June 1—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Eli Lilly and Company as a specialty pharmacy provider for RETEVMO™ (selpercatinib), the first drug approved by the U.S....

Recent Posts

  • ORGOVYX™ (relugolix), the First FDA-Approved Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer, Available at Biologics by McKesson
  • A Letter to Our Biopharma Clients About Organizational Changes
  • Video Transcript: PBMI Specialty Rx Forum on Maintaining Patient Centeredness
  • Video Transcript: McKesson’s Paula Bickley on Maintaining Patient Centeredness
  • GAVRETO™ (pralsetinib), FDA Approved for Treatment of Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer, Available at Biologics by McKesson

Archives

  • January 2021
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • January 2020
  • August 2019
  • July 2019
  • March 2019
  • December 2018
  • September 2018
  • July 2018
  • June 2018
  • May 2018
  • February 2018
  • January 2018
  • June 2017
  • March 2017
  • February 2016
  • November 2015
  • February 2015
  • December 2014
Biologics by McKesson logo

13000 Weston Parkway
Suite 105
Cary, NC 27513
T. 800.850.4306*

 

Legal
Privacy Notice
Terms of Use

For Patients
Privacy Practices (pdf)
Patient’s Rights (pdf)

Learn more about McKesson

URAC accreditation seal Biologics 2023 ACHC Gold Seal Accreditation ACHC Blue Seal Accreditation in Oncology

 

Home
Patients
Providers
Payers
Biopharma
News
Careers
About Us
Leadership
Contact
Resources

© 2019 McKesson Corporation. All Rights Reserved.